Gorjan Hrustanovic

CIK: 0001821194

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

KYMR

Kymera Therapeutics, Inc.

Director

OLMA

Olema Pharmaceuticals, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

KYMR
Kymera Therapeutics, Inc.
Jun 24, 2026
Award(A)
Stock Option (Right to Buy)
Direct
6.1K shares-
OLMA
Olema Pharmaceuticals, Inc.
Jun 18, 2026
Award(A)
Stock Option (right to buy)
Direct
29.5K shares-
KYMR
Kymera Therapeutics, Inc.
Jun 25, 2025
Award(A)
Stock Option (Right to Buy)
Direct
16K shares-
OLMA
Olema Pharmaceuticals, Inc.
Jun 11, 2025
Award(A)
Stock Option (right to buy)
Direct
24.2K shares-

		Type	Shares	Price		Ownership
Jun 24, 2026	KYMR Kymera Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	6,068	-	-	Direct
Jun 18, 2026	OLMA Olema Pharmaceuticals, Inc.	Award(A) Stock Option (right to buy)	29,500	-	-	Direct
Jun 25, 2025	KYMR Kymera Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	16,000	-	-	Direct
Jun 11, 2025	OLMA Olema Pharmaceuticals, Inc.	Award(A) Stock Option (right to buy)	24,150	-	-	Direct

1-4 of 4 transactions

About Hrustanovic Gorjan

Hrustanovic Gorjan (SEC CIK 0001821194) files insider reports with the SEC as Director of Kymera Therapeutics, Inc. (KYMR) and Director of Olema Pharmaceuticals, Inc. (OLMA).

Signal8 holds 4 ownership filings by Hrustanovic Gorjan, all Form 4s, filed between Jun 13, 2025 and Jun 25, 2026. Those filings report 4 transactions, from Jun 11, 2025 to Jun 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Hrustanovic Gorjan's filings is in SAN FRANCISCO, CA.

Recent filings by Hrustanovic Gorjan

Jun 24, 2026: Grant or award of KYMR derivative securities (Form 4, code A).
Jun 18, 2026: Grant or award of OLMA derivative securities (Form 4, code A).
Jun 25, 2025: Grant or award of KYMR derivative securities (Form 4, code A).
Jun 11, 2025: Grant or award of OLMA derivative securities (Form 4, code A).

Other insiders filing for Kymera Therapeutics, Inc. (KYMR)

Mainolfi Nello, Chief Executive Officer
Adams Brian, Chief Legal Officer
Rooney Terence, Chief Medical Officer
Jacobs Bruce N., Chief Financial Officer
Goodman Noah, Chief Business Officer
Booth Bruce, Director

How to read Form 4 transaction codes